top of page
Browse by category
Search
Palatin's oral MC4R Agonist PL7737 receives FDA Orphan Drug Designation for obesity due to leptin receptor deficiency
Palatin Technologies has announced the FDA has granted "orphan drug" designation to PL7737, an oral treatment that activates the...
Palatin completes Phase 2 obesity study with MC4R bremelanotide + Tirzepatide
Palatin Technologies has completed its Phase 2 BMT-801 clinical study of the co-administration of MC4R bremelanotide + GLP-1/GIP...
Palatin completes study enrolment of bremelanotide plus tirzepatide to treat obesity
Palatin Technologies has completed enrolment in the study entitled "BMT-801, A Phase II, Randomized, Double-Blind, Placebo-Controlled,...
Palatin initiates study of bremelanotide for the treatment of obesity
Palatin Technologies has begun a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate...
Palatin to investigate MC4R agonist as a potentially effective and safe treatment for obesity
Palatin Technologies, a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of...
Browse by tag
bottom of page